Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H7N9 Influenza Vaccine
NCT03196661Phase 1Completed
- Sponsor
- Hualan Biological Vaccine Inc.
- Start
- Nov 2015
- Primary completion
- Jul 2016
- Modality
- Whole Inactivated Vaccines
01
Overview
Phase 1, randomised, double-blind trial of Influenza A (H7N9) virus vaccine in Influenza A H7N9 Infection (H7N9) (4 arms), sponsored by Hualan Biological Vaccine Inc. Primary endpoints: Local adverse reactions and Systemic adverse reactions. Started Nov 2015; status: completed.
02
Drugs
Influenza A (H7N9) virus vaccine
03
Conditions
Influenza A H7N9 Infection (H7N9)
Beyond the preview
Go deeper on NCT03196661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196661.